Cascadian Therapeutics, Inc.
DelistedCIK 1412067fmd_10QMESY7DN8KQBXJQG3MT1H7RMServices · Services-Commercial Physical & Biological ResearchTemplate: Standard
Coverage: Jan 01, 2009 to Dec 31, 2017, 32 periods
Latest annual · FY2017
Millions- Operating income
- (58)
- Net income
- (57)
- Free cash flow
- (50)
Latest quarter · Q4 FY2017
Millions- Operating income
- (17)
- Net income
- (17)
- Free cash flow
- (12)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2012 to FY2017
- n/m
Cascadian Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2017 | FY2016 | Change | Source |
|---|---|---|---|---|
| Operating income | -$58.1 million | -$64.8 million | 10-K 2018-03-08 · proof | |
| Net income | -$56.9 million | -$57.7 million | 10-K 2018-03-08 · proof | |
| Cash from operating activities | -$50 million | -$36.7 million | 10-K 2018-03-08 · proof | |
| Free cash flow | -$50.1 million | -$36.9 million | 10-K 2018-03-08 · proof | |
| Total assets | $120.8 million | $83.3 million | +45.1% | 10-K 2018-03-08 · proof |
| Total liabilities | $11.8 million | $8.9 million | +32.3% | 10-K 2018-03-08 · proof |
| Cash and cash equivalents | $16.8 million | $13.7 million | +22.3% | 10-K 2018-03-08 · proof |
- What was Cascadian Therapeutics, Inc.'s operating income in fiscal 2017?
- Cascadian Therapeutics, Inc. reported operating income of -$58.1 million for fiscal 2017 (the year ended Dec 31, 2017), against -$64.8 million the year before. Source: the 10-K filed with the SEC on Mar 8, 2018. SEC
- What was Cascadian Therapeutics, Inc.'s net income in fiscal 2017?
- Cascadian Therapeutics, Inc. reported net income of -$56.9 million for fiscal 2017 (the year ended Dec 31, 2017), against -$57.7 million the year before. Source: the 10-K filed with the SEC on Mar 8, 2018. SEC
- What was Cascadian Therapeutics, Inc.'s cash from operating activities in fiscal 2017?
- Cascadian Therapeutics, Inc. reported cash from operating activities of -$50 million for fiscal 2017 (the year ended Dec 31, 2017), against -$36.7 million the year before. Source: the 10-K filed with the SEC on Mar 8, 2018. SEC
- What was Cascadian Therapeutics, Inc.'s free cash flow in fiscal 2017?
- Cascadian Therapeutics, Inc. reported free cash flow of -$50.1 million for fiscal 2017 (the year ended Dec 31, 2017), against -$36.9 million the year before. Source: the 10-K filed with the SEC on Mar 8, 2018. SEC
- What are Cascadian Therapeutics, Inc.'s total assets?
- As of Dec 31, 2017, Cascadian Therapeutics, Inc. reported total assets of $120.8 million, against $83.3 million a year earlier (+45.1%). Source: the 10-K filed with the SEC on Mar 8, 2018. SEC
- What are Cascadian Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2017, Cascadian Therapeutics, Inc. reported total liabilities of $11.8 million, against $8.9 million a year earlier (+32.3%). Source: the 10-K filed with the SEC on Mar 8, 2018. SEC
- What are Cascadian Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2017, Cascadian Therapeutics, Inc. reported cash and cash equivalents of $16.8 million, against $13.7 million a year earlier (+22.3%). Source: the 10-K filed with the SEC on Mar 8, 2018. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1412067&period_type=annual&limit=5"Information only, not investment advice.